[Notice - March 19, 2026]

NOTICE OF SCHEDULED MAINTENANCE – ReBEC

Please be advised that the ReBEC system will undergo a scheduled maintenance outage, beginning at 6:00 p.m. on March 20, 2026 (Friday) and expected to end at 6:00 p.m. on March 22, 2026 (Sunday).

During this period, the system will be unavailable for access and for performing any operations. This measure is necessary to implement improvements and updates aimed at ensuring greater stability, security, and performance of the platform.

We recommend that users plan ahead to avoid any potential disruptions to their activities.

Thank you for your understanding.
ReBEC Coordination

PRIORITY SERVICES

The Brazilian Registry of Clinical Trials (ReBEC) presents the new fast tracks for clinical research and observational studies on INDIGENOUS PEOPLE AND TRADITIONAL COMMUNITIES and on NEGLECTED TROPICAL DISEASES (NTDs). Fast-track can reduce the normal approval period for clinical trials to less than 48 hours, if the documentation, information and any mandatory changes requested are provided by the registrant.

The already existing fast-tracks and the attendance to other studies will not be interrupted. Priority care is granted with a view to accelerating clinical research in epidemiological emergency situations and/or studies with the potential to reduce socioeconomic inequalities, keeping the perspective aligned with the forefront of ethics and transparency, diplomacy in health, scientific collaboration and diversity and specificities of recruitment and health care.

FAST-TRACKS IN OPERATION:

I - Indigenous Peoples, Traditional Communities, Human Migration and Refugee Movements – clinical research and observational studies dedicated to or preferably addressing traditional communities (quilombola, caiçara, faxinalense, among others), Indigenous peoples (within or outside legally demarcated territories), and refugee groups, taking into account the specificities established by regulation, on a case-by-case basis.

II - Neglected Tropical Diseases – Leprosy, Tuberculosis, Leishmaniasis, Schistosomiasis, Scabies, Chagas disease, Intestinal parasitoses, Viral hepatitis, Trachoma, Onchocerciasis, Human rabies transmitted by dogs.

III - National and International Public Health Emergencies – Mpox, Covid-19.

IV - Arboviruses – Zika, Dengue, Chikungunya, Malaria, Yellow fever.

V - WHO Prioritized Pathogens for Latin America – Studies dealing with World Health Organization prioritized pathogens for Latin America, as listed in the document "PATHOGENS PRIORITIZATION - A SCIENTIFIC FRAMEWORK FOR EPIDEMIC AND PANDEMIC RESEARCH PREPAREDNESS" (Health Emergencies Programme, 2024) – Lassa fever, Cholera, Black Death (Plague), Bacillary dysentery or Shigellosis, Salmonella, Pneumonia, Urinary tract infection, MERS-CoV, SARS, Ebola virus (EVE), Marburg virus (MVE), Ebola virus (EVE) Sudan subtype, Hantavirus pulmonary syndrome (HPS), Hemorrhagic fever with renal syndrome (HFRS), Crimean-Congo hemorrhagic fever, Influenza A H1, Influenza A H2, Influenza A H3, Avian influenza (Influenza A H5N1), Avian influenza (Influenza A H6), Avian influenza H7 (Avian influenza H7), Avian influenza H10 or Avian influenza H10, Nipah disease, Viral hemorrhagic disease, Poliomyelitis, Hand-foot-and-mouth disease, Herpangina, Viral meningitis, Smallpox, Mpox, Human Immunodeficiency Virus (HIV), Venezuelan equine encephalitis (VEE).

VI - WHO Prioritized Prototype Pathogens for Latin America – Studies dealing with World Health Organization prioritized prototype pathogens for Latin America, as listed in the document "PATHOGENS PRIORITIZATION - A SCIENTIFIC FRAMEWORK FOR EPIDEMIC AND PANDEMIC RESEARCH PREPAREDNESS" (Health Emergencies Programme, 2024) – Recombinant mastadenovirus, Mastadenovirus blackbeardi serotype 14, Mammarenavirus juninense, Mammarenavirus lujoense, Mamastrovirus virginiaense, Orthobornavirus bornaense, Orthoflavivirus encephalitidis, Orthoflavivirus nilense, Orthohepadnavirus hominoidae genotype C, Paslahepevirus balayani genotype 3, Protoparvovirus carnivoran, Orthobunyavirus oropoucheense, Phlebovirus riftense, Orthopicobirnavirus hominis, Enterovirus alphacoxsackie 71, Enterovirus deconjuncti 68, Metapneumovirus hominis, Orthopoxvirus vaccinia, Genus Vesiculovirus, Genus Rotavirus, Orthoreovirus mammalis.

VII - Studies on the impacts of climate change, the effects of scientific denialism, and health misinformation -The physical, mental, and social consequences of environmental and climate changes on human populations; The impact of extreme weather events and environmental degradation on infectious, chronic, or emerging diseases; The influence of denialist narratives and misinformation in Health on adherence to preventive measures, vaccination, treatments, and risk behaviors, as well as the physical and mental outcomes for human beings and populations.

INSTRUCTIONS:

We recommend reading the Registrant Handbook. Material available at LINK.

1. Register or log in and normally fill out the forms in Portuguese and English. For English, in case of difficulty, use the Google Translate tool (or another free translation tool).
2. Attach the mandatory ethics committee documentation and submit the form.
3. Register the service number on your Whatsapp. Send a message with your name and login. IT IS NOT NECESSARY NOR RECOMMENDED TO SEND YOUR PASSWORD.
4. A reviewer will respond to you. Choose the service modality: chat, audio recordings or voice call by appointment.
5. Your form will be proofread in both languages. Follow the remaining guidelines to finalize the approval.

CONTACTS:

Support is online, via chat, dedicated telephone line (see phone number below) and WhatsApp, from 9 am to 5 pm (Brasília time).

Administrative, priority and/or urgent matters outside office hours: plantao.rebec@gmail.com
Line 1: +55 21 97203-4750

ABOUT REBEC:

The Brazilian Registry of Clinical Trials (ReBEC) is a free access virtual platform for recording experimental and non-experimental studies carried out on human beings and conducted in Brazilian territory, by Brazilian and foreign researchers. ReBEC is a joint project of the Ministry of Health (DECIT/MS), the Pan American Health Organization (OPAS) and the Oswaldo Cruz Foundation (FIOCRUZ). ReBEC's Executive Committee is composed of the aforementioned institutions and the National Health Surveillance Agency (ANVISA).

05/11/2026  |  Hannover Medical School  |  Medical Xpress

https://medicalxpress.com/news/2026-05-rna-therapy-heart-remodeling-clinical.html 

Following an acute heart attack, pathological remodeling processes occur in the heart. One consequence is so-called left ventricular systolic dysfunction, in which the pumping function of the left ventricle is impaired. To compensate for this, the heart muscle enlarges excessively, thereby becoming further weakened. The key regulator of this harmful growth of heart muscle cells is microRNA-132 (miR-132).

A team led by Prof. Dr. Thomas Thum, Director of the Institute for Molecular and Translational Therapeutic Strategies at Hannover Medical School (MHH), has produced a synthetic antagonist called CDR132L, which can block the main switch for cardiac hypertrophy and reverse chronic heart failure. The researchers have already demonstrated this in animal models and early clinical trials.

The drug candidate CDR132L has now been investigated in an international Phase II clinical trial involving patients who have recently suffered a heart attack and have heart failure. The HF-REVERT study has shown that patients with already advanced cardiac remodeling at the start of the study could benefit particularly from treatment with CDR132L. The results of the study were published in the journal Nature Medicine.

MicroRNA regulates pathological heart muscle growth
MicroRNA molecules belong to a class of molecules known as non-coding RNA (ncRNA), meaning they are not translated into specific proteins. Instead, they regulate a wide range of cellular processes—such as how a cell grows, whether it divides, or what type of cell it develops into. On the other hand, excessive microRNA activity can alter gene regulation and thereby trigger diseases.

One example of this is miR-132.…

05/11/2026  |  Michael Farkouh  |  New Wise

https://www.newswise.com/articles/understanding-clinical-trials-what-patients-need-to-know 

What is a clinical trial? Are they safe? Are they free? Who can participate?

These are among the most common questions patients ask when they consider joining a clinical trial at Cedars-Sinai, where more than 700 such studies are currently underway.

Those trials are essential to advancing medical care and offer patients access to emerging new therapies while helping researchers better understand diseases and improve future treatments, said Michael Farkouh, MD, vice dean for Research and Clinical Trials at Cedars-Sinai Health Sciences University.

“A clinical trial is the final step in translating research innovations into clinical practice—the bridge from research discovery to the patient,” Farkouh said. “As an academic medical center, Cedars-Sinai provides excellent clinical care alongside access to novel therapies that can enhance that care.”

To mark Clinical Trials Awareness Month, the Cedars-Sinai Newsroom spoke with Farkouh about how patients can decide whether a clinical trial is right for them.

What is a clinical trial?
A clinical trial is a carefully designed study that evaluates new drugs, devices or care strategies in eligible patients who choose to participate. A clinical trial typically compares a new approach with the current standard of care to determine whether it leads to better outcomes. If it does, it may become part of routine medical practice.

What are the phases of clinical trials?
Each phase serves a distinct purpose. Phase I focuses on safety, helping researchers determine whether a new treatment can be used safely in people.

Phase II evaluates whether the treatment…

05/11/2026 | Anvisa

https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-produtos-a-base-de-cannabis 

The Brazilian Health Regulatory Agency (Anvisa) ruled on Monday (May 11) to ban the sale and promotion of the cannabis-derived products Allandiol Forte Black 1:1 and Allandiol Full Spectrum 300 mg, manufactured by Instituto Alma Viva Ltda. 

The Agency identified the promotion and sale of cannabis-derived products under the Biocase/Allandiol brands without registration or health authorization, which are mandatory requirements to ensure the safety, efficacy, and quality of the products. The company in question does not hold an Operating Authorization (AFE) to manufacture or market this type of product.

The irregularities were found on the company’s website and Instagram profile, where the products were offered and their alleged therapeutic benefits were promoted without health approval. The measure also applies to any person or company that advertises, sells, or promotes these products, due to the risk to public health. 

Packaging 

After the company announced the voluntary recall of lots 111626C, 111750C, and 112056C of the drug Kefazol – 1 g powder for injectable solution (CT FA VD Trans x 10 ml), Anvisa suspended the marketing, distribution, and use of the product. The action was prompted by a quality deviation related to a failure in the packaging process. 

05/08/2026  |  Andrea Lobo  |  ALS News Today

https://alsnewstoday.com/news/new-ai-matchmaker-quickly-pairs-als-patients-clinical-trials/ 

EverythingALS reports 92% success rate in identifying eligible research studies

EverythingALS has launched a new online tool called SAVA AI that uses artificial intelligence to instantly match people with amyotrophic lateral sclerosis (ALS) to clinical trials.

The platform is available for free through the EverythingALS website or as a mobile app, providing patients with a secure way to find research opportunities they may be eligible for in real time.

By entering their health information into the tool, users receive immediate alerts about relevant studies and can share those findings with their doctors and families. This digital resource aims to remove the guesswork from finding experimental treatments, ensuring that a patient’s location or personal connections do not limit their access to care.

“We created SAVA AI because access to clinical trials should never depend on chance, geography, or connections,” Indu Navar, founder and CEO of EverythingALS, said in a press release. “By harnessing AI and citizen-driven research, we’re giving patients the power to find opportunities that could change the course of their own disease journey, and accelerating the entire community’s path toward a cure.”

Navigating the challenges of clinical trial enrollment
After an ALS diagnosis, finding clinical trial opportunities quickly is often a vital part of a patient’s care plan. While currently approved treatments can help manage symptoms or slightly slow the progression of the disease, their impact is often limited. This leads many patients to seek out clinical trials to access experimental…

05/08/2026  |  Cláudio Isaías  |  Jornal do Comércio

https://www.jornaldocomercio.com/geral/2026/05/1247860-futuro-da-pesquisa-e-acesso-a-tratamentos-inovadores-serao-discutidos-no-clinical-research-summit.html 

With the aim of discussing clinical research in Brazil and Latin America, the 2nd edition of the Clinical Research Summit 2026 will be held on May 12 and 13 in Porto Alegre. The initiative brings together experts from Brazil and abroad.

Organized by Moinhos de Vento Hospital, the event features the participation of Professor Kaj Blennow from the University of Gothenburg (Sweden), one of the world’s leading authorities on biomarkers for neurodegenerative diseases, particularly Alzheimer’s. Cardiologist and researcher André Zimerman, from Moinhos de Vento Hospital, states that every treatment a patient receives today was once clinical research.

“Treatments have to be studied, and there is an entire process, from an idea to the creation of a drug and testing on humans,” he comments. According to Zimerman, the event was created to discuss clinical research in Brazil and Latin America. The cardiologist notes that Brazil was long left out of the clinical research landscape. “Recently, it has become heavily involved in participating in foreign studies, and now Brazil and Latin America are increasingly taking the lead in research,” he adds.

With over 1,000 scientific publications and extensive involvement in global initiatives, Blennow is recognized for leading advances that are transforming disease diagnosis, including the development of tests based on biological fluids, such as blood and cerebrospinal fluid, capable of identifying changes earlier and with greater precision.